Aphria Triples Production Capacity With Health Canada Approval

Leamington-based marijuana producer, Aphria, has received a license amendment from Health Canada to increase production.

The approval will provide Aphria with an additional 200,000 square feet of production space as part of its phase three expansion at the Leamington facility.

The company says this will more than triple production capacity of medical marijuana from nearly 9,000 kg a year to more than 30,000 kg.

The company is now working on part four of its expansion plan, and in a release, CEO Vic Neufled says "when completed early next year, our fully expanded facility will provide over 1,000,000 square feet of production space and, when combined with our strategic relationship with Double Diamond Farms and our recent acquisition of Broken Coast Cannabis, will bring our anticipated production capacity to 230,000 kg per year."

The expansions will enable Aphria to meet the expected demand from the Canadian market, while allowing a significant portion to be allocated to key established international markets.